BLC
AMRX icon

Brown, Lisle/Cummings’s Amneal Pharmaceuticals AMRX Stock Holding History

Brown, Lisle/Cummings’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63K Buy
+325
New +$4.45K ﹤0.01% 687

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Brown, Lisle/Cummings's AMRX Position: Q2 2026 in Review

Brown, Lisle/Cummings opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 325 shares worth $5.63K. The stake represents ﹤0.01% of the portfolio and ranks #687 among its holdings.

311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Brown, Lisle/Cummings held 325 shares of Amneal Pharmaceuticals worth $5.63K as of Q2 2026.
  • Amneal Pharmaceuticals was a new Brown, Lisle/Cummings position in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #687 holding.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.